|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Aupérin A, Le Péchoux C, Rolland E, Curran
WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus
R, et al: Meta-analysis of concomitant versus sequential
radiochemotherapy in locally advanced non-small-cell lung cancer. J
Clin Oncol. 28:2181–2190. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vaupel P and Mayer A: Hypoxia in cancer:
Significance and impact on clinical outcome. Cancer Metastasis Rev.
26:225–239. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nordsmark M, Bentzen SM, Rudat V, Brizel
D, Lartigau E, Stadler P, Becker A, Adam M, Molls M, Dunst J, et
al: Prognostic value of tumor oxygenation in 397 head and neck
tumors after primary radiation therapy. An international
multi-center study. Radiother Oncol. 77:18–24. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Le QT: Identifying and targeting hypoxia
in head and neck cancer: A brief overview of current approaches.
Int J Radiat Oncol Biol Phys. 69(Suppl 2): S56–S58. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Höckel M and Vaupel P: Biological
consequences of tumor hypoxia. Semin Oncol. 28(2): Suppl 8.
S36–S41. 2001. View Article : Google Scholar
|
|
7
|
Zips D, Böke S, Kroeber T, Meinzer A,
Brüchner K, Thames HD, Baumann M and Yaromina A: Prognostic value
of radiobiological hypoxia during fractionated irradiation for
local tumor control. Strahlenther Onkol. 187:306–310. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bache M, Kappler M, Said HM, Staab A and
Vordermark D: Detection and specific targeting of hypoxic regions
within solid tumors: Current preclinical and clinical strategies.
Curr Med Chem. 15:322–338. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Le QT and Courter D: Clinical biomarkers
for hypoxia targeting. Cancer Metastasis Rev. 27:351–362. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vordermark D and Brown JM: Endogenous
markers of tumor hypoxia predictors of clinical radiation
resistance? Strahlenther Onkol. 179:801–811. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ostheimer C, Bache M, Güttler A, Kotzsch M
and Vordermark D: A pilot study on potential plasma hypoxia markers
in the radiotherapy of non-small cell lung cancer. Osteopontin,
carbonic anhydrase IX and vascular endothelial growth factor.
Strahlenther Onkol. 190:276–282. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ostheimer C, Bache M, Güttler A, Reese T
and Vordermark D: Prognostic information of serial plasma
osteopontin measurement in radiotherapy of non-small-cell lung
cancer. BMC Cancer. 14:8582014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bradley JD, Leumwananonthachai N, Purdy
JA, Wasserman TH, Lockett MA, Graham MV and Perez CA: Gross tumor
volume, critical prognostic factor in patients treated with
three-dimensional conformal radiation therapy for non-small-cell
lung carcinoma. Int J Radiat Oncol Biol Phys. 52:49–57. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Koo TR, Moon SH, Lim YJ, Kim JY, Kim Y,
Kim TH, Cho KH, Han JY, Lee YJ, Yun T, et al: The effect of tumor
volume and its change on survival in stage III non-small cell lung
cancer treated with definitive concurrent chemoradiotherapy. Radiat
Oncol. 9:2832014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Werner-Wasik M, Swann RS, Bradley J,
Graham M, Emami B, Purdy J and Sause W: Increasing tumor volume is
predictive of poor overall and progression-free survival: Secondary
analysis of the Radiation Therapy Oncology Group 93-11 phase I–II
radiation dose-escalation study in patients with inoperable
non-small-cell lung cancer. Int J Radiat Oncol Biol Phys.
70:385–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Basaki K, Abe Y, Aoki M, Kondo H, Hatayama
Y and Nakaji S: Prognostic factors for survival in stage III
non-small-cell lung cancer treated with definitive radiation
therapy: Impact of tumor volume. Int J Radiat Oncol Biol Phys.
64:449–454. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cox DR: Regression models and life tables.
J Royal Stat Soc Series B (Methodological). 34:187–220. 1972.
|
|
18
|
Isa S, Kawaguchi T, Teramukai S, Minato K,
Ohsaki Y, Shibata K, Yonei T, Hayashibara K, Fukushima M, Kawahara
M, et al: Serum osteopontin levels are highly prognostic for
survival in advanced non-small cell lung cancer: Results from JMTO
LC 0004. J Thorac Oncol. 4:1104–1110. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mack PC, Redman MW, Chansky K, Williamson
SK, Farneth NC, Lara PN Jr, Franklin WA, Le QT, Crowley JJ, et al:
Lower osteopontin plasma levels are associated with superior
outcomes in advanced non-small-cell lung cancer patients receiving
platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol.
26:4771–4776. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Blasberg JD, Pass HI, Goparaju CM, Flores
R, Lee S and Donington JS: Reduction of elevated plasma osteopontin
levels with resection of non-small-cell lung cancer. J Clin Oncol.
28:936–941. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Alexander BM, Othus M, Caglar HB and Allen
AM: Tumor volume is a prognostic factor in non-small-cell lung
cancer treated with chemoradiotherapy. Int J Radiat Oncol Biol
Phys. 79:1381–1387. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kozak MM, Murphy JD, Schipper ML,
Donington JS, Zhou L, Whyte RI, Shrager JB, Hoang CD, Bazan J,
Maxim PG, et al: Tumor volume as a potential imaging-based
risk-stratification factor in trimodality therapy for locally
advanced non-small cell lung cancer. J Thorac Oncol. 6:920–926.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Stinchcombe TE, Morris DE, Moore DT,
Bechtel JH, Halle JS, Mears A, Deschesne K, Rosenman JG and
Socinski MA: Post-chemotherapy gross tumor volume is predictive of
survival in patients with stage III non-small cell lung cancer
treated with combined modality therapy. Lung Cancer. 52:67–74.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ball DL, Fisher RJ, Burmeister BH, Poulsen
MG, Graham PH, Penniment MG, Vinod SK, Krawitz HE, Joseph DJ,
Wheeler GC and McClure BE: The complex relationship between lung
tumor volume and survival in patients with non-small cell lung
cancer treated by definitive radiotherapy: A prospective,
observational prognostic factor study of the Trans-Tasman radiation
oncology group (TROG 99.05). Radiother Oncol. 106:305–311. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yamane Y, Ishii G, Goto K, Kojima M, Nakao
M, Shimada Y, Nishiwaki Y, Nagai K, Kohrogi H and Ochiai A: A novel
histopathological evaluation method predicting the outcome of
non-small cell lung cancer treated by neoadjuvant therapy: The
prognostic importance of the area of residual tumor. J Thorac
Oncol. 5:49–55. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Soliman M, Yaromina A, Appold S, Zips D,
Reiffenstuhl C, Schreiber A, Thames HD, Krause M and Baumann M: GTV
differentially impacts locoregional control of non-small cell lung
cancer (NSCLC) after different fractionation schedules: Subgroup
analysis of the prospective randomized CHARTWEL trial. Radiother
Oncol. 106:299–304. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wigren T: Confirmation of a prognostic
index for patients with inoperable non-small cell lung cancer.
Radiother Oncol. 44:9–15. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Contal C and O'Quigley J: An application
of changepoint methods in studying the effect of age on survival in
breast cancer. Comput Stat Data Anal. 30:253–270. 1999. View Article : Google Scholar
|
|
29
|
Le QT, Kong C, Lavori PW, O'byrne K, Erler
JT, Huang X, Chen Y, Cao H, Tibshirani R, Denko N, et al:
Expression and prognostic significance of a panel of tissue hypoxia
markers in head-and-neck squamous cell carcinomas. Int J Radiat
Oncol Biol Phys. 69:167–175. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Le QT, Chen E, Salim A, Cao H, Kong CS,
Whyte R, Donington J, Cannon W, Wakelee H, Tibshirani R, et al: An
evaluation of tumor oxygenation and gene expression in patients
with early stage non-small cell lung cancers. Clin Cancer Res.
12:1507–1514. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chu KP, Murphy JD, La TH, Krakow TE,
Iagaru A, Graves EE, Hsu A, Maxim PG, Loo B, Chang DT and Le QT:
Prognostic value of metabolic tumor volume and velocity in
predicting head-and-neck cancer outcomes. Int J Radiat Oncol Biol
Phys. 83:1521–1527. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee P, Bazan JG, Lavori PW, Weerasuriya
DK, Quon A, Le QT, Wakelee HA, Graves EE and Loo BW: Metabolic
tumor volume is an independent prognostic factor in patients
treated definitively for non-small-cell lung cancer. Clin Lung
Cancer. 13:52–58. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Choi YW, Munden RF, Erasmus JJ, Park KJ,
Chung WK, Jeon SC and Park CK: Effects of radiation therapy on the
lung: Radiologic appearances and differential diagnosis.
Radiographics. 24:985–998. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zips D, Zöphel K, Abolmaali N, Perrin R,
Abramyuk A, Haase R, Appold S, Steinbach J, Kotzerke J and Baumann
M: Exploratory prospective trial of hypoxia-specific PET-imaging
during radiochemotherapy in patients with locally advanced
head-and-neck cancer. Radiother Oncol. 105:21–28. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Joseph S, Harrington R, Walter D, Goldberg
JD, Li X, Beck A, Litton T, Hirsch N, Blasberg J, Slomiany M, et
al: Plasma osteopontin velocity differentiates lung cancers from
controls in a CT screening population. Cancer Biomark. 12:177–184.
2012.PubMed/NCBI
|
